In conclusion, EGF+GHRP6-based therapy is biologically plausible as a therapeutic intervention, given that both serum levels of EGF and insulin-like growth factor-1 (IGF-1) (as the main effect induced by GHRP6) were substantially lower in stroke patients and are determinant factors of ischemic stroke outcomes (76, 77). This evidence concerns the gene IGF1 and Stroke.